Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Director | December 19, 2025 | December 19, 2025 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Chief Operating Officer | July 05, 2022 | July 05, 2022 |
| Zymeworks Inc.ZYME · Entity 4458 | President & COO | March 10, 2023 | March 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date December 19, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2030-12-18 | Direct | 5,250 |
Reported balance
After 2025-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-19 · Grant · Acquired 1,750 · Balance 5,250 F1: The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner.
Zymeworks BC Inc.
Report date July 05, 2022 · Filed July 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 14,801 |
Reported balance
After 2022-07-05 transaction · row 1
1 source rowRow 1 · 2022-07-05 · Grant · Acquired 1,525 · Balance 14,801 F1: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2022 through June 30, 2022. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2022. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by spouse | 700 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 700 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2022 through June 30, 2022. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2022.
Zymeworks Inc.
Report date March 10, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,032 |
Ending reported balance
After 2023-03-10 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-03-10 · Exercise / conversion · Acquired 2,500 · Balance 17,301 F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020. Row 2 · 2023-03-10 · Exercise / conversion · Acquired 2,708 · Balance 20,009 F2: Represents shares of common stock issued upon vesting of one third of the RSUs granted on March 10, 2021. Row 3 · 2023-03-10 · Sale · Disposed 2,977 · Balance 17,032 F3: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.815 to $7.86, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-10 · Exercise / conversion · Disposed 2,500 · Balance 0 F5: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F6: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 2,709 |
Reported balance
After 2023-03-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-10 · Exercise / conversion · Disposed 2,708 · Balance 2,709 F5: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7: The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022. |
| Common StockSEC Table I · non-derivative | IndirectHeld by spouse | 700 |
Reported balance
Holding disclosure · report date 2023-03-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 700 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020.
F2: Represents shares of common stock issued upon vesting of one third of the RSUs granted on March 10, 2021.
F3: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.815 to $7.86, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F6: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021.
F7: The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2025 Filed Dec 19, 2025 16:42 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,750 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001213900-25-123636 · ownership.xml · derivative · entry 1 Klompas Neil A · CIK 0001761857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 Underlying: Common shares · 1,750 shares Expires 2030-12-18 F1 · derivative.exercise_date: The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner. Read SEC document |
| October 17, 2025 Filed Oct 21, 2025 17:58 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001213900-25-100720 · ownership.xml · derivative · entry 1 Klompas Neil A · CIK 0001761857 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Underlying: Common shares · 3,500 shares Expires 2030-10-16 F1 · derivative.exercise_date: (1) The options were granted on Oct 17, 2025 and will vest monthly, in arrears, as follows: (i) 98 stock options will vest on the 17th day of each month for 35 months, and (ii) 70 stock options will vest on Oct 17, 2025 (the three year anniversary of Grant date). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 17:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008432 · doc4.xml · derivative · entry 6 Klompas Neil A · CIK 0001761857 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,709 Underlying: Common Stock · 2,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022. F7 · derivative.expiration_date: The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 17:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008432 · doc4.xml · derivative · entry 5 Klompas Neil A · CIK 0001761857 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. F6 · derivative.expiration_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 17:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 2,977 | $7.83 | $23,297.70 |
DisclosureSEC source: 0000899243-23-008432 · doc4.xml · nonDerivative · entry 3 Klompas Neil A · CIK 0001761857 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,032 F3 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.815 to $7.86, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 17:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008432 · doc4.xml · nonDerivative · entry 2 Klompas Neil A · CIK 0001761857 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Represents shares of common stock issued upon vesting of one third of the RSUs granted on March 10, 2021. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 17:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008432 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 58,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001219 · doc4.xml · derivative · entry 2 Klompas Neil A · CIK 0001761857 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,500 Underlying: Common Stock · 58,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on January 5, 2024. F3 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on January 5, 2024. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 20:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 87,500 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001219 · doc4.xml · derivative · entry 1 Klompas Neil A · CIK 0001761857 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2033-01-04 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| July 05, 2022 Filed Jul 5, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 1,525 | $4.51 | $6,877.75 |
DisclosureSEC source: 0000899243-22-025151 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,801 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2022 through June 30, 2022. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2022. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010795 · doc4.xml · derivative · entry 7 Klompas Neil A · CIK 0001761857 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2032-03-09 F8 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionRestricted Stock Unit · Derivative | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010795 · doc4.xml · derivative · entry 6 Klompas Neil A · CIK 0001761857 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,417 Underlying: Common Shares · 2,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022. F7 · derivative.expiration_date: The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010795 · doc4.xml · derivative · entry 5 Klompas Neil A · CIK 0001761857 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. F6 · derivative.expiration_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Shares | 2,979 | $6.88 | $20,495.52 |
DisclosureSEC source: 0000899243-22-010795 · doc4.xml · nonDerivative · entry 3 Klompas Neil A · CIK 0001761857 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,276 F3 · kind: Represents common shares sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (each, a "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. The Reporting Person is subject to a Lock Up Agreement that expires on March 27, 2022. The sale of shares is a permissible exemption under the terms of the Lock Up Agreement. The remaining shares held by the Reporting Person following this sale remain subject to the terms of the Lock Up Agreement. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.83 to $6.97, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010795 · doc4.xml · nonDerivative · entry 2 Klompas Neil A · CIK 0001761857 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Represents common shares issued upon vesting of one third of the RSUs granted on March 10, 2021. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010795 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020. Read SEC document |
| January 07, 2022 Filed Jan 7, 2022 21:30 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 277 | $13.94 | $3,861.38 |
DisclosureSEC source: 0000899243-22-001423 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,047 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2021 through December 31, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on December 31, 2021. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 299 | $29.49 | $8,817.51 |
DisclosureSEC source: 0000899243-21-027913 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,770 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2021 through June 30, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantRestricted Stock Unit · Derivative | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-011433 · doc4.xml · derivative · entry 6 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125 Underlying: Common Shares · 8,125 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on March 10, 2022. F7 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on March 10, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 48,750 | $0.00 Strike: $34.82 | $0.00 |
DisclosureSEC source: 0000899243-21-011433 · doc4.xml · derivative · entry 5 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Shares · 48,750 shares Expires 2031-03-09 F6 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-011433 · doc4.xml · derivative · entry 4 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. F5 · derivative.expiration_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Shares | 1,425 | $34.95 | $49,808.74 |
DisclosureSEC source: 0000899243-21-011433 · doc4.xml · nonDerivative · entry 2 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,471 F2 · kind: Represents common shares sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person irrevocably adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.80 to $35.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-011433 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 21:24 UTC Amendment | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 284 | $30.92 | $8,781.28 |
DisclosureSEC source: 0000899243-21-001421 · doc4a.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,396 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2020 through December 31, 2020. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on July 1, 2020. F2 · balance_after: The Form 4 originally filed is being amended to correct the inadvertent overstatement of the "Amount of Securities Beneficially Owned Following Reported Transactions" by ten (10) shares in Table I, column 5. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 17:04 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 284 | $30.92 | $8,781.28 |
DisclosureSEC source: 0000899243-21-001342 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,406 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2020 through December 31, 2020. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on July 1, 2020. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 19:30 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,620 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0000899243-20-033634 · doc4.xml · derivative · entry 6 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,330 Underlying: Common Shares · 16,620 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of the stock option is CAD7.26. The U.S. dollar equivalent of the exercise price is $5.6708 using the Bank of Canada exchange rate for December 9, 2020 (CAD1.00 = $0.7811). F4 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following the first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 19:30 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,380 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0000899243-20-033634 · doc4.xml · derivative · entry 5 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,380 shares Expires 2022-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price of the stock option is CAD5.37. The U.S. dollar equivalent of the exercise price is $4.1945 using the Bank of Canada exchange rate for December 9, 2020 (CAD1.00 = $0.7811). F4 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following the first anniversary of grant date. The grant date was ten years before the listed expiration date. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 19:30 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Shares | 25,000 | $53.25 | $1,331,132.50 |
DisclosureSEC source: 0000899243-20-033634 · doc4.xml · nonDerivative · entry 3 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,122 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.00 to $53.95, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 9, 2020 at each separate price. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 19:30 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 16,620 | $5.67 | $94,248.70 |
DisclosureSEC source: 0000899243-20-033634 · doc4.xml · nonDerivative · entry 2 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price of the stock option is CAD7.26. The U.S. dollar equivalent of the exercise price is $5.6708 using the Bank of Canada exchange rate for December 9, 2020 (CAD1.00 = $0.7811). Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 19:30 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 8,380 | $4.19 | $35,149.91 |
DisclosureSEC source: 0000899243-20-033634 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price of the stock option is CAD5.37. The U.S. dollar equivalent of the exercise price is $4.1945 using the Bank of Canada exchange rate for December 9, 2020 (CAD1.00 = $0.7811). Read SEC document |
| December 09, 2020 Filed Jan 11, 2021 21:42 UTC Amendment | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Shares | 25,000 | $53.25 | $1,331,132.50 |
DisclosureSEC source: 0000899243-21-001427 · doc4a.xml · nonDerivative · entry 3 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,112 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.00 to $53.95, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 9, 2020 at each separate price. F4 · balance_after: The Form 4 originally filed is being amended to correct the inadvertent overstatement of the "Amount of Securities Beneficially Owned Following Reported Transactions" by ten (10) shares in each of the first three rows of Table I, column 5. Read SEC document |
| December 09, 2020 Filed Jan 11, 2021 21:42 UTC Amendment | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 16,620 | $5.67 | $94,248.70 |
DisclosureSEC source: 0000899243-21-001427 · doc4a.xml · nonDerivative · entry 2 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price of the stock option is CAD7.26. The U.S. dollar equivalent of the exercise price is $5.6708 using the Bank of Canada exchange rate for December 9, 2020 (CAD1.00 = $0.7811). F4 · balance_after: The Form 4 originally filed is being amended to correct the inadvertent overstatement of the "Amount of Securities Beneficially Owned Following Reported Transactions" by ten (10) shares in each of the first three rows of Table I, column 5. Read SEC document |
| December 09, 2020 Filed Jan 11, 2021 21:42 UTC Amendment | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 8,380 | $4.19 | $35,149.91 |
DisclosureSEC source: 0000899243-21-001427 · doc4a.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price of the stock option is CAD5.37. The U.S. dollar equivalent of the exercise price is $4.1945 using the Bank of Canada exchange rate for December 9, 2020 (CAD1.00 = $0.7811). F4 · balance_after: The Form 4 originally filed is being amended to correct the inadvertent overstatement of the "Amount of Securities Beneficially Owned Following Reported Transactions" by ten (10) shares in each of the first three rows of Table I, column 5. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 19:41 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 277 | $30.66 | $8,492.82 |
DisclosureSEC source: 0000899243-20-018546 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,112 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2020 through June 30, 2020. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2020. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:25 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantRestricted Stock Unit · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-008001 · doc4.xml · derivative · entry 2 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Shares · 7,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on March 10, 2021. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on March 10, 2021. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:25 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0000899243-20-008001 · doc4.xml · derivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2030-03-09 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 16:05 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 394 | $19.54 | $7,698.76 |
DisclosureSEC source: 0000899243-20-000877 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,835 F1 · kind: Shares purchased pursuant to the issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2019 through December 31, 2019. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the issuer's common shares on July 1, 2019. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 16:54 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 464 | $12.49 | $5,795.36 |
DisclosureSEC source: 0000899243-19-019435 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,441 F1 · kind: Shares purchased pursuant to the issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2019 through June 30, 2019. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the issuer's common shares on January 2, 2019. Read SEC document |
| May 06, 2019 Filed May 8, 2019 16:27 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,380 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0000899243-19-012640 · doc4.xml · derivative · entry 7 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,380 shares Expires 2019-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The exercise price of the stock option is CAD4.75. The U.S. dollar equivalent of the exercise price is $3.53 using the Bank of Canada exchange rate for May 6, 2019 (CAD1.00 = $0.7432). F6 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date of July 1, 2009, and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| May 06, 2019 Filed May 8, 2019 16:27 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,704 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0000899243-19-012640 · doc4.xml · derivative · entry 6 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,704 shares Expires 2019-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price of the stock option is CAD3.58. The U.S. dollar equivalent of the exercise price is $2.66 using the Bank of Canada exchange rate for May 6, 2019 (CAD1.00 = $0.7432). F5 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date of July 1, 2007, and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| May 06, 2019 Filed May 8, 2019 16:27 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Stock | 1,604 | $19.25 | $30,877.96 |
DisclosureSEC source: 0000899243-19-012640 · doc4.xml · nonDerivative · entry 4 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,977 F4 · price: The shares were sold in multiple transactions and the price reported is a weighted average. The sale prices ranged from $19.13 to $19.365. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2019 Filed May 8, 2019 16:27 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Stock | 8,380 | $3.53 | $29,581.40 |
DisclosureSEC source: 0000899243-19-012640 · doc4.xml · nonDerivative · entry 3 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The exercise price of the stock option is CAD4.75. The U.S. dollar equivalent of the exercise price is $3.53 using the Bank of Canada exchange rate for May 6, 2019 (CAD1.00 = $0.7432). Read SEC document |
| May 06, 2019 Filed May 8, 2019 16:27 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Stock | 6,704 | $19.22 | $128,854.90 |
DisclosureSEC source: 0000899243-19-012640 · doc4.xml · nonDerivative · entry 2 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,201 F2 · price: The shares were sold in multiple transactions and the price reported is a weighted average. The sale prices ranged from $19.07 to $19.48. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2019 Filed May 8, 2019 16:27 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Stock | 6,704 | $2.66 | $17,832.64 |
DisclosureSEC source: 0000899243-19-012640 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price of the stock option is CAD3.58. The U.S. dollar equivalent of the exercise price is $2.66 using the Bank of Canada exchange rate for May 6, 2019 (CAD1.00 = $0.7432). Read SEC document |
| March 27, 2019 Filed Mar 28, 2019 16:45 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $15.23 | $0.00 |
DisclosureSEC source: 0000899243-19-009170 · doc4.xml · derivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2029-03-26 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 17:49 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $15.53 | $0.00 |
DisclosureSEC source: 0000899243-19-000993 · doc4.xml · derivative · entry 2 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Shares · 90,000 shares Expires 2029-01-07 F2 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 17:49 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 414 | $12.48 | $5,166.72 |
DisclosureSEC source: 0000899243-19-000993 · doc4.xml · nonDerivative · entry 1 Klompas Neil A · CIK 0001761857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,201 F1 · kind: Shares purchased pursuant to the issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2018 through December 31, 2018. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the issuer's common shares on December 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.